← Back to all trials
Completed
NCT07169942
Aleniglipron Phase 2 Body Composition Study
Conditions: Obesity, Overweight, or Chronic Weight Management
Sex: All
Ages: 18 Years – 79 Years
Healthy volunteers: No
Phase: PHASE2
Enrollment: 71
Sponsor: Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Location: Research Site Phoenix Arizona
Summary
This is a randomized, double-blind, placebo-controlled study evaluating the effects of aleniglipron on body composition in participants living with obesity. Participants will be randomized to aleniglipron or placebo in a ratio of 5:1. Participants will receive multiple ascending QD doses of aleniglipron or placebo in titration steps of 4 weeks duration for a total of 44 weeks of treatment.
Eligibility Criteria
Inclusion Criteria:
* Signed informed consent
* Participants age ≥18 years and \1 year prior to screening)
* Have obesity induced by other endocrine disorders (such as Cushing's syndrome, Prader-Willi syndrome, or melanocortin 4 receptor deficiency)
Source: ClinicalTrials.gov (NCT07169942). StuddyBuddy aggregates publicly available trial information.
